牛牛AI助理已提取核心訊息
On February 2, 2024, Cardio Diagnostics Holdings, Inc. completed a private placement transaction with seven accredited investors, issuing 561,793 units for gross proceeds of $1,000,000. Each unit consists of one share of common stock and a six-year warrant to purchase additional shares at $1.78 each. The company plans to register these shares and warrants for resale within 180 days and has granted the investors rights to participate in future financings until February 2, 2025, with certain exceptions. The placement agent, Altitude Capital Group, LLC, received a 10% commission and 20% warrant coverage on the transaction. The company's Chairman of the Board, Dr. Warren Hosseinion, who holds a 10% interest in Altitude Capital, recused himself from board decisions regarding the placement. The funds raised are intended for working capital and general corporate purposes. The securities were issued in reliance on exemptions from registration requirements under the Securities Act of 1933.
On February 2, 2024, Cardio Diagnostics Holdings, Inc. completed a private placement transaction with seven accredited investors, issuing 561,793 units for gross proceeds of $1,000,000. Each unit consists of one share of common stock and a six-year warrant to purchase additional shares at $1.78 each. The company plans to register these shares and warrants for resale within 180 days and has granted the investors rights to participate in future financings until February 2, 2025, with certain exceptions. The placement agent, Altitude Capital Group, LLC, received a 10% commission and 20% warrant coverage on the transaction. The company's Chairman of the Board, Dr. Warren Hosseinion, who holds a 10% interest in Altitude Capital, recused himself from board decisions regarding the placement. The funds raised are intended for working capital and general corporate purposes. The securities were issued in reliance on exemptions from registration requirements under the Securities Act of 1933.
2024年2月2日，Cardio Diagnostics Holdings, Inc.完成了與七名合格投資者的私募交易，發行了561,793套，總收益爲100萬美元。每個單位由一股普通股和一份六年期認股權證組成，用於以每股1.78美元的價格購買額外股票。該公司計劃在180天內註冊這些股票和認股權證進行轉售，並已授予投資者在2025年2月2日之前參與未來融資的權利，但有某些例外情況。配售代理機構Altitude Capital Group, LLC從該交易中獲得了10％的佣金和20％的認股權證。該公司董事會主席沃倫·霍塞尼恩博士持有Altitude Capital10％的權益，他迴避了董事會關於此次配售的決定。籌集的資金用於營運資金和一般公司用途。這些證券是根據1933年《證券法》的註冊要求豁免發行的。
2024年2月2日，Cardio Diagnostics Holdings, Inc.完成了與七名合格投資者的私募交易，發行了561,793套，總收益爲100萬美元。每個單位由一股普通股和一份六年期認股權證組成，用於以每股1.78美元的價格購買額外股票。該公司計劃在180天內註冊這些股票和認股權證進行轉售，並已授予投資者在2025年2月2日之前參與未來融資的權利，但有某些例外情況。配售代理機構Altitude Capital Group, LLC從該交易中獲得了10％的佣金和20％的認股權證。該公司董事會主席沃倫·霍塞尼恩博士持有Altitude Capital10％的權益，他迴避了董事會關於此次配售的決定。籌集的資金用於營運資金和一般公司用途。這些證券是根據1933年《證券法》的註冊要求豁免發行的。
有用
沒用